NCT01000493 - Orvepitant (GW823296) in Adult Post Traumatic Stress Disorder | Biotech Hunter

Enrollment

132

Participants

Timeline

Start Date

November 2, 2009

Primary Completion Date

June 28, 2010

Study Completion Date

June 28, 2010

Conditions

Post-Traumatic Stress Disorder

Interventions

DRUG

orvepitant

Neurokinin-1 (NK-1) antagonist

OTHER

Placebo

Inactive placebo to match orvepitant 60 mg dosage form

Trial Locations (26)

10467

GSK Investigational Site, The Bronx

21061

GSK Investigational Site, Glen Burnie

27609

GSK Investigational Site, Raleigh

29403

GSK Investigational Site, Charleston

30060

GSK Investigational Site, Marietta

32216

GSK Investigational Site, Jacksonville

32806

GSK Investigational Site, Orlando

35216

GSK Investigational Site, Birmingham

38119

GSK Investigational Site, Memphis

44125

GSK Investigational Site, Garfield Heights

45417

GSK Investigational Site, Dayton

46260

GSK Investigational Site, Indianapolis

53223

GSK Investigational Site, Brown Deer

53562

GSK Investigational Site, Middleton

60068

GSK Investigational Site, Park Ridge

74104

GSK Investigational Site, Tulsa

75231

GSK Investigational Site, Dallas

77008

GSK Investigational Site, Houston

78756

GSK Investigational Site, Austin

85251

GSK Investigational Site, Scottsdale

90210

GSK Investigational Site, Beverly Hills

90502

GSK Investigational Site, Torrance

98104

GSK Investigational Site, Seattle

02190

GSK Investigational Site, Weymouth

08046

GSK Investigational Site, Willingboro

84132-2502

GSK Investigational Site, Salt Lake City